Haeyong Chung
Lead Independent DirectorDr. Haeyong Chung, also known as Lauren, Ph.D., M.B.A., serves as an Independent Director of Profusa, Inc. since July 11, 2025. She was Chief Financial Officer of Laxxon Medical Corp. from October 2024 until August 2026 and served as its Director from October 2024. She joined Laxxon Medical Corp. in October 2024. She served as Independent Director at Genenta Science S.p.A. from May 02, 2024 until 2025. She had been Independent Director of Aditxt, Inc. (formerly known as ADiTx Therapeutics, Inc.) since June 2021 until December 31, 2021. She serves as an Independent Director at Footura Inc. She had been an Independent Director at CURE Pharmaceutical Holding Corp. since August 6, 2019 until November 30, 2021. Dr. Chung serves as Lead Independent Director at Todos Medical Ltd since April 2020. She served as Independent Director at NorthView Acquisition Corporation from December 2021 to July 2025. Dr. Chung was a Managing Director of Healthcare Research and Publishing Equity Analyst at WestPark Capital, Inc., Research Division since 2017 until April 2019. Dr. Chung served as a Publishing Equity Analyst covering the micro-cap life sciences sector. She serves as Director at UltraSight, Inc. and ADiTx Therapeutics Inc. She served as a Senior Equity Analyst at Maxim Group LLC, Research Division from 2016 to 2017 and focused on healthcare companies. Earlier, Dr. Chung was an Analyst at Maxim Group LLC, Research Division. Previously, she provided consulting services related to healthcare investments and various strategic and operational planning for healthcare companies and investment firms. Dr. Chung was a Co-Founder and Chief Operating Officer at Tokum Capital Management. Prior to that, she was a Healthcare Portfolio Manager and Analyst at RBR Capital, Kingdon Capital and Pequot Capital from 2001 to 2006. Dr. Chung has equity research and investment management experience in the biotechnology and healthcare space. Dr. Chung serves as a Board Member in private healthcare companies. Dr. Chung was a research scientist doing cutting-edge work in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital. Dr. Chung serves as Independent Director at Todos Medical Ltd since April 2020. From May 2017 to November 2019, Dr. Chung was an Equity Research Managing Director at WestPark Capital. From August 2016 to April 2017, Dr. Chung as in equity research at Maxim Group. Dr. Chung has published in many leading peer-reviewed scientific journals. Dr. Chung is the Founder and CEO of MINLEIGH LLC since November 2019 which is focused on identifying, evaluating and Partnering with companies for investments and strategic, operational and commercial opportunities. She has healthcare investment management, investment banking and advisory experience and is a Venture Partner at Yozma Group Asia Headquartered in South Korea. Dr. Chung holds a Ph.D. in Neuropathology, Biomedical Sciences from Columbia University-College of Physicians & Surgeons, an M.B.A. from Columbia Business School and a BA with honors in Biochemistry and Economics from Wellesley College.
Positions
- Company NameTodos Medical Ltd.Stock CodeTOMDFPositionLead Independent DirectorColleagues
- Company NameProfusa, Inc.Stock CodeNVACWPositionIndependent DirectorRelated SecuritiesColleagues
- CHChung-Bin HwangPresident
- JEJack E. StoverCEO & Executive Chairman
- FSFred S. KnechtelChief Financial Officer
- WMWilliam McMillanCo-founder, Chief Scientific Officer & Head of Research
- DIDavid IckeHead of Digital Health Business
- HCHaeyong ChungIndependent Director
- RJRajesh J. AsorpotaIndependent Director
- PMPeter M. O’RourkeLead Independent Director
- LGLiviu GoldenbergIndependent Director
